Non-Alcoholic Steatohepatitis Treatment Market Players:
- Intercept Pharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer, Inc.
- Inventiva
- Galmed Pharmaceuticals Ltd.
- Novo Nordisk A/S
- Madrigal Pharmaceuticals
- Galectin Therapeutics
- NGM Biopharmaceuticals
- Bristol-Myers Squibb Company
- Can Fite
- Zydus Lifesciences Ltd.
- Mitsubishi Chemical Group Corporation
- Shilpa Medicare Ltd.
- Hepion Pharmaceuticals, Inc.
Key players in the non-alcoholic steatohepatitis treatment market are evolving their dynamics with the introduction of new therapeutics and preventive medicines. As the trend of identifying and treating the root cause grows, companies are increasingly focusing on developing targeted therapies for individual needs. For instance, in October 2024, Boehringer Ingelheim accomplished Breakthrough Therapy designation for its dual glucagon/GLP-1 receptor agonist, survodutide, from the FDA. This results from the phase II clinical trials demonstrated significant improvement in adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis. The company further commenced the phase III trial for testing the drug’s ability in treating MASH and cirrhosis. Such key innovators are:
